# Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

> **NCT06977594** · NA · NOT_YET_RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer

## Interventions

- **OTHER:** Proactive immune tolerance induction
- **OTHER:** Standard Treatment
- **DRUG:** Paclitaxel and carboplatin
- **DRUG:** Standard premedication (20 mg)
- **DRUG:** Reduced premedication (10 mg)
- **DRUG:** Reduced premedication (5 mg)

## Key facts

- **NCT ID:** NCT06977594
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977594, "Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06977594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*